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ABSTRACT 
Carlin & Louis (1985) propose a selection procedure designed to control the problems of 
multiplicity associated with P-values reported from carcinogen bioassays. Instead of 
searching the data for statistically significant tumor site/type combinations, the procedure 
uses site/type specific prior information and conditioning statistics to select sites and 
types with potentially significant P-values. Any single P-value selected by this method 
retains its usual meaning, and the size of the test procedure is controlled. We apply the 
Carlin & Louis procedure to a random sample of bioassays using male and female mice and 
rats from the National Cancer Institute's data base. From these data we estimate priors 
for lifetime incidence ~nd dose effect. Then, we compare the performance of the selection 
procedure to use of Bonferroni adjusted and unadjusted minimum observed P-values. 
Estimated priors for the OCLartttnc12. of any malignancy show that over all strata prevalence 
in controls is about 25%, and that generally there is a positive association between dose 
and malignancy. Mice are far more sensitive than rats, with male rats the least sensitive. 
The association between dose and survival to terminal sacrifice shows a negative associa-
tion with dose, so control rodents tend to live longer than others, suggesting that proper 
analysis should adjust for time until tumor. For all tumor sites, generally the prior stan-
dard deviation on the dose is effect is high, allowing the bioassay to contribute important 
information on determining carcinogenicity. The liver, mammary gland, spleen, and skin 
show at least a moderate positive dose effect, while site lymphosarcomas show a con-
sistently negative association between dose and lifetime tumor incidence. 
Our investigation indicates that the conditional selection approach has a rejection rate for 
the 5% level test competitive with unadjusted minimum P-values, and generally greater 
than that for adjusted P-values. Certain sites are picked quite fre-
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quently. These sites have generally high a priori .power, but the conditional power fre-
quently does change the a priori indications. Plots of the empirical cumulative distribu-
tion functions for the P-values selected by the various rules show that the conditional 
selection approach produces a distribution that is between that for unadjusted and the 
Bonferroni adjusted minimum observed P-values. Theoretical development supports these 
observations. 
The present analysis is primarily demonstrative. Our data-base does not contain informa-
tion on time to tumor, dose, or cause of death. Conditional selection procedures using this 
information depend on straightforward technical generalizations of the Carlin and Louis 
procedure. But, specifying priors for target and nuisance parameters and implementing 
the selection rule pose serious challenges. Even with the current data each step of the 
analysis could be improved. Estimated priors could incorporate the full effect of estimat-
ing parameters (Morris 1983, Laird and Louis 1986), or the non-parametric maximum likel-
ihood estimate of priors (Laird 1982) could replace those based on the Gaussian assump-
tion. In practice, priors should be developed using a combination of information on chemi-
cals with similar structure and expert opinion. Models could combine evidence on the pri-
ors over gender and strain. 
Though the regulatory setting is too complicated to permit selection of a single site for 
analysis, use of our procedure to prioritize sites will focus debate. If statistical significance 
appears in a low-priority site, the burden of proof will be to justify the finding. If a high-
priority site is significant, the burden switches to arguing why the result should not be 
believed. As important, much of the debate would occur before the experiment during the 
construction of priors. 
Finally, we should remember that statistical significance computed from P-values provides 
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only one type of input into the risk assessment process. Yet, P-values do carry a great 
deal of weight, and increasing their validity will improve the risk assessment process. The 
previously noted extensions and refinements will be required before the selection pro-
cedure becomes "on-line". This development depends on the efforts and expertise of Toxi-
cologists, Pathologists, Statisticians, Computer scientists and other experts. However, the 
effort and expense should be justified by the expense of the bioassay and its importance in 
the risk assessment process. 
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1. INTRODUCTION 
In the typical carcinogen bioassay numerous statistical tests are performed simultaneously. 
Within each of the four common species-sex combinations (male-female, mice-rats), there 
may be 30 or more site and tumor-type combinations examined for tumors. A test statistic 
is calculated for each using a trend test for monotone dose response or pair-wise dose corn-
parisons (see Lagakos and Louis 1985). 
In the situation of a single species-sex combination with only one test statistic per site-
type pair, the chance of obtaining at least one significant result under the null hypothesis 
of no treatment effect can be as high as 1-- (1- 0t)K, where K is the number of sites and a 
is the nominal level. This classical multiple comparisons problem can be circumvented by 
requiring the minimum individual P-value to be below a.lk (the Bonferroni method), but 
determination of k and the loss of power makes this approach unattractive (Mantel 1980). 
Recent research (Haseman 1983,5) suggests that in practice the multiplicity problem is not 
really serious, because the effects of discrete data and biological judgement produce an 
overall false positive rate that is quite close to the nominal level. The basic argument ori-
ginates with Fears, Tarone, and Chu (1977). Dempster and Meng (1985) propose a more 
formal approach to the multiplicity problem based on a random effects model, and Finkel-
stein and Schoenfeld develop a single test statistic based on total tumors. 
Carlin and Louis (1985) summarize these arguments and develop a method of selecting 
tumor sites for analysis using the conditional expected power (or the conditional expected 
P-value) of the test procedure for each site. Margins of two-way tables used in the analysis 
provide the conditioning and the procedure depends on prior distributions for site-specific 
tumor prevalence and dose effect. Sites with the highest conditional expected power (for a 
pre-selected significance level) or the smallest conditional expected P-value are selected for 
,, 
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the dose group comparison. Since site selection is based on prior information and table 
marginals (conditioning statistics for the usual frequentist analyses of these experiments), 
the selection process does not induce problems of multiplicity. In addition, standard 
reporting and interpretations are valid. The procedure has the potential to focus analysis 
and interpretation on a small number of sites and tumor types, but its statistical proper-
ties have not yet been investigated either theoretically or empirically. 
In this report we apply the selection procedure to data from a random sample of carcino-
gen bioassays conducted by the National Cancer Institute (see Young 1986). We use these 
data to estimate site, gender, and species (mouse and rat) specific prior distributions for 
tumor prevalence and dose effect. Then, we apply the Carlin and Louis selection pro-
cedure and compare results to those using adjusted and unadjusted minimum observed P-
values. We find that the power of the procedure compares favorably with that for unad-
justed P-values, w bile controlling the overall size of the test procedure. Theoretical 
development supports this observation. 
In section 2 we present the Carlin and Louis procedure; section 3 describes the data base, 
outlines the method of estimating of priors, and the method of comparing selection rules. 
Section 4 presents results, section 5 gives some theoretical background, and we close with 
a discussion in section 6. 
2. THE CARLIN & LOUIS PROCEDURE 
2.1 General setting 
In this section we describe a general approach to picking one from a number of tests and 
then adapt the method to the carcinogen bioassay. Consider selecting a single test statis-
tic from those available in such a way that the size of the selected test is unaffected by 
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multiplicity, and standard analysis and interpretations are valid. The procedure uses prior 
information about the likely magnitude of the non-centrality parameter for each test, and 
ancillary or partially ancillary information from the data, the latter based on a condition-
ing statistic. For conditional tests typically used in the bioassay (see Lagakos and Louis 
1986) we use marginal tumor totals. P-values are conditional on such totals and so are 
free from multiple comparisons distortion, if only totals are used to select a single test 
statistic for the dose group comparison. 
Suppose we are processing a number of results summarized by significance tests (P-values) 
for a scalar parameter 8. A single test uses data X to compare the null hypothesis 8 = 0 to 
the alternative e > 0. We consider frequentist P-values: 
PVAL = pr(T(X) > T(z) 10==0), (2.1) 
where T( ·) is a test statistic. We judge the single test significant, if PVAL s a, for some 
pre-determined cut-off. 
Before seeing the P-values we want to choose the experiment that has the greatest statisti-
cal power. With a prior distribution (G) for 8 we average over the parameter space 0, 
producing the expected power for a single test: 
EP(cx)= E(pr(PVALsa)] = J pr(PVALScx l0)dG(0). 
9 
(2.2) 
In examining EP we are focusing on one feature of the distribution of the random variable 
"PVAL", namely the 100(1-cx)% quantile. Other statistics may be of interest, especially 
ones that do not depend on a, such as the mean and variance of the distribution of 
"PVAL". For discrete data computing the complete distribution of "PVAL" is no more 
difficult than computing a single feature. Definition (2.2) can be extended to give the 
expected power conditional on a statistic by conditioning on the statistic in both "pr( ·)" 
and G. 
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Using this conditional expected power, or any other feature of the conditional distribution 
of the P-value to select a test statistic induces no problems of multiplicity, even if the 
statistics are correlated. 
2.2 Comparing Binomial Distributions 
Although bioassays commonly are conducted with a control group and two or three dose 
groups, we have implemented the procedure only for pair-wise comparisons based on 
Fisher's exact test. Consider two groups of size n0 (control) and n1 (treated). Members of 
each group are examined for the presence or absence of tumors at several sites and of 
several types. For a single site and type, we denote by "T" the number of tumor-bearing 
animals in the treated group, and by "S" the total number of tumor-bearing animals (see 
Figure 1). Letting Po and p1 denote the tumor rates, we test H0 :p1 =p0 versus 
Parameterizing in the logit scale, we write: 
and 
µ = logit(p0)- log( 1 Po J, -po 
e = logit(pi)- logit(p0). 
The null and alternative hypotheses translate into 8 = O and 8 > O, where e should be con-
sidered the slope on the logistic dose-response curve with the treated animals receiving 
dose "I". With more than two groups, 8 would multiply the actual dose or log dose. 
The frequentist similar test results from conditioning on S, producing: 
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( no ) r nl) et 
pr(T==tlS==a,µ,S)-pr(T-tlS=a,e)- 8 -t te , 
io (a~JJ ( ;1) ee; (2.3} 
where a binomial coefficient is set to 0, if the bottom is bigger than the top. This non-
central hypergeometric distribution is free of the nuisance parameter µ. At S = 0 we have 
the standard Fisher's exact test. 
For this testing problem the marginal distribution of S does depend on S as well as on µ, 
so the distribution (2.3) fails to use all the information relevant to e. This information 
loss is particularly acute when S is near 0 or n 0 + n 1 • A full Bayesian analysis would incor-
po rate this information, but in this report we use the standard conditional analysis. Thus, 
in order to obtain the conditional distribution of PVAL given S for use in (2.2) we corn-
pute, (assuming that G has a density g): 
pra(T- t IS= a] ... J J pr( T== t IS= a ,0)g(µ. ,e IS= a )dµ de. (2.4) 
Substituting (2.3) into (2.4) and using Bayes' rule produces: 
prc[T=tlS=a) at [ ~t) ["/)JJ e"'+et g(µ.,S)dµd0. 8 (1 + e"')"O(l + e"H)"1 (2.5) 
From 2.5 we can produce the conditional expected power: 
EPOWa(S,a)== pra(PVALsalS), (2.6) 
and the conditional expectation (EP a(S]) and variance (VP 0 (S]) of the P-value. 
Generally, calculation of (2.5) requires a numerical method, and Carlin and Louis discuss 
possible approaches. In the subsequent analyses we use independent Gaussian priors for µ. 
and e and a monte-carlo evaluation method that samples directly from the joint distribu-
tion of(µ. ,S). For fixed(µ. ,S) the joint distribution of (S,T) is the product of binomial pro-
babilities. To compute the conditional distribution, pr0 (T=tlS=s), we accumulate the 
values -0f the joint probabilities over a large sample of (IJ. ,9) pairs drawn from g. 
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Conditional 
probabilities result from normalizing the vector of joint probabilities. We control numeri-
cal problems in calculating the binomial probabilities by computing one reference binomial 
distribution using Pascal's triangle recursion and calculating the others by multiplying 
this reference by the appropriate factor. With 10,000 replications the procedure runs 
rapidly on an IBM/ AT and produces numerically stable results. 
3. DATA AND METHODS 
3.1 The data base 
Young (1986) and compamon papers by Bickis and Krewski {1986); Louis (1986); and 
Sanathanan et al ( 1986) give details on the data set and analyses. Twenty-five chemicals 
were selected at random from the NCI data base. For each chemical, data were obtained 
on four associated experiments (males and females, mice and rats). Thus, the data set con-
tains information from 100 bioassays. One pair of the mouse experiments was set aside, 
leaving data on 98 experiments. 
Data from each experiment consist of dose and site-specific lifetime tumors (malignant and 
non-malignant), a summary of dose-specific lifetime rates of having any tum or (per rodent, 
any tumor generates an "event"; denoted ALL in our tables), and dose-specific numbers of 
rodents surviving to terminal sacrifice. The data base contains no direct information on 
time to tumor and we coded doses "O", ".5", and "l ". We base the current investigation on 
data for malignant tumors and use unadjusted lifetime rates. We estimated priors only for 
those tumor sites and types with at least one tumor in at least 10 experiments within a 
sex/strain stratum; with a separate determination in each stratum. The data base only 
lists sites where at least one tum or occurs, but for estimating the control rates, we use all 
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experiments, imputing zero tumors for the sites not reported. 
3.2 Estimating priors 
To implement the selection rule we need gender and strain-specific prior distributions for 
µ and e. We estimate these priors using a simple variance components analysis that 
separately estimates the prior on the control rate and dose effect. More sophisticated 
approaches to this empirical Bayes analysis can be taken (Stiratelli et al 1984), but this 
approach will serve our present purpose. 
Consider estimating a prior for µ from data (X.1;,n.1;), k= 1, ... ,K, where X.1; is the number 
of tumor-bearing control rodents and n.1; is the number of rodents for the k1h experiment. 
The X's come from a compound model where for each X.1: a µ is drawn from the prior and 
then, conditional on µ., X follows a binomial distribution with success probability 
p= e!.1./(1 + ei.i.). First we estimate the prior distribution for the logistic normal random 
variable "P", and then transform it to a distribution forµ.. 
Estimates are based on the method of moments, by equating the observed weighted sample 
mean and variance to their expectation under the assumption that the prior mean and 
variance are related as in a beta distribution. Following Louis and DerSimonian (1982), 
estimate the expectation ( m) and the variance ( '1'2) of P by: 




D-mO-ml ] ... 
(1-l;pl) , 
n+ K-1 I 
where 
I I 
Also, assuming the beta distribution relation, we can compute the precision ( C) of the beta 
prior, defined by: 
0 .,,,.m(l-m) 
,.2 • 
The value (C-1) plays the role of an effective sample size for this conjugate prior to the 
binomi~I distribution. We use C in transforming to a prior on J.L. 
Failing to account for the uncertainty in this estimated prior can cause problems. These 
problems can be seen most dramatically when "1"2 ==0. The prior induces a constant under-
lying tumor rate from experiment to experiment, since the estimated posterior distribution 
is degenerate at m. Morris (1983), and Laird and Louis (1986) discuss this issue. Morris 
uses a delta-theorem expansion, and Laird and Louis use the bootstrap to introduce esti-
mation uncertainty into the prior. 
For a simple fixup, we introduce the uncertainty in estimating m by reducing the precision 
so that the prior variance includes a summand for the variance of m in a manner similar 
to that discussed by Morris (1983) for posterior distributions. Specifically, let 
and 
C == C • -------"-+ ___ _ 
n+(l+l:pE)+ c.-1 
If C <1.01, we set it equal to 1.01. 
Notice that C < C • and if C •=co ( f 2 == 0), then C = n +, introducing some variance into the 
prior. More sophisticated adjustments can be used, but this method will serve the present 
purpose. 
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Now, we convert the beta prior to a Gaussian prior-on µ by: 
E( ) I [ Cm + .5 l µ "" og C(l-m)+.5 
V()""'[c2l 1 
µ C-l (Cm+.5)1C{l-m)+.5]' 
in analogy to empirical logits. 
We estimate the prior for 8 using the method in Louis (1986). He uses the Z-score for a 
trend test comparing dose groups to impute an estimate of 8 and a variance of this esti-
mate for each experiment and then processes these estimates assuming a two-stage Gaus-
sian sampling process. We use the control and two dose groups in this analysis, with the 
dose effect parameterized by: 
logit[p.,., 0( d)] .... µ + de. 
The trend test Z-score can be represented as Z=U/B, where "U" is a score statistic and B2 
is the estimated variance of the score statistic (computed from the table marginal) under 
the null hypothesis that 8 = 0. For logistic dose-response curves and small 8, E6(Z)~ SB, 
so we estimate ek for the kth experiment by Sk'"" ZiBk. We estimate the sampling variance 
of this estimate by, Ve= Bk- 2, then process these (eA:, Vk) pairs with an iterative maximum 
likelihood variance components program that produces estimates of the prior mean and 
variance of e. Then, we adjust the prior variance as described below. This approach 
depends on similar dose spacings in all experiments within a gender/strain stratum. These 
bioassays were conducted according to standard NCI protocols with most using the MTD, 
50%MTD, and control, so a degree of similarity can be expected. 
We adjust the prior variance (T2)for uncertainty in the prior estimates by first estimating 
the variance via maximum likelihood, producing -r"2 and then adding Q- 1, where: 
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Q == l:( V1; + T"2t1. 
I; 
This adjustment can be motivated by considering a Bayes model where the prior mean and 
variance have an noninformative hyper-prior. Then, using iterated expectations and vari-
ances, the mean of 6 is approximately the estimated prior mean, and its variance is 
approximately T ' 2 plus the variability of the estimated prior mean. The value Q- 1 esti-
mates this variance. 
3.3 Comparing selection rules 
For the high dose versus control test we compared the empirical rejection/acceptance rates 
of Carliµ and Louis selection rules to the minimum observed P-value with and without 
adjustment. We applied the selection rules to data from the four strata, each with and 
without deleting "ALL" from contention, and for the two mouse strata also without allow-
ing Ll934 (liver hepatocellular carcinoma) to be selected. The minimum observed P-values 
were left unadjusted, inflated by the Y K (Mantel 1980), and by K (Bonferroni), where K 
is the number of site/type combinations in the experiment that have at least one tumor. 
For example, though we allow up to 34 sites to produce the minimum P-value, if only six 
sites have tumors, we multiply by six. Therefore, the adjustment for multiplicity is also 
conditional on one aspect of the margins. Even though the selection criteria relate to the 
high-dose versus control comparison, in addition we compared rules where observed P-
value was computed from the trend test based on controls and two doses, but with site-
selection rules based on the high- dose versus control 2 X 2 tables. 
We summarize results by summaries of sites selected by the various rules, a series of 2X 2 
tables classifying the P-values above or below a, the cumulative distribution of P-values 
for selected sites, test statistics comparing computed probability of rejecting the null with 
the actual rejections, and statistics assessing the fit of the conditional expected P-values to 
those observed. We have applied both score and chi- square tests. The score test 
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computes: 
and the chi-square is: 
}:(YESf-EP0 ) 
aites 
[}: EP0 (1-EP0 ))"' 
1ites 
}: (YESP- EP0 )2 ' 
sitea EP a(I - EP aJ 
where YES! indicates if the P-value is below a. Similar computations apply to the 
observed and expected P-values. 
4. RESULTS 
4.1 Estimated Priors 
Our use of tumors where at least four experiments provide information on 8 (had at least 
one tumor) produced estimates for 34 sites. Tables la-d display estimated priors for sites 
where at least 10 experiments provided information on 8, and Table 2 gives the tumor 
types. The "ALL" rows show that over all strata prevalence in controls is about 25%, and 
that generally there is a positive association between dose and malignancy. Mice are far 
more sensitive than rats (look at the E(8) columns), with male rats the least sensitive. The 
"SURV" rows indicate the association between dose and survival to terminal sacrifice. 
They show a negative association with dose, so control rodents tend to live longer than 
others, suggesting that proper analysis should adjust for time until tumor. For all tumor 
sites, generally the prior standard deviation on 8 is high, allowing the bioassay to contri-
bute important information on determining carcinogenicity. Sites ALL, Ll934, MG902, 
SP932, SP939, SK972 show at least a moderate positive dose effect, while site MU939 
shows a consistently negative association between dose and lifetime tumor incidence. The 
negative association between m and C suggests a departure from the beta distribution's 
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relation between mean and variance. The logistic dose-response relation probably doesn't 
hold at low doses. 
4.2 Comparing Selection rules 
Table 3 displays a selected set of comparisons between the conditional expected power and 
minimum P-value selection rules for nominal 5% level tests. They indicate that the condi-
tional approach has a rejection rate competitive with unadjusted minimum P-values, and 
generally greater than that for adjusted P-values. Of course, we have no gold standard to 
determine a correct decision. Table 4 shows that certain sites ( eg. LI934 for mice), are 
picked quite frequently. These sites have generally high a priori power, but the condi-
tional power frequently does change the a priori indications. For example, when ALL is 
removed from contention, in mice Ll934 is picked in 36 of the 48 experiments. When both 
ALL and LI 934 are removed, site selections are. quite variable. Interestingly, though E(9) 
for MU939 is negative and has a relatively small prior standard deviation, it is picked. 
Conditioning on the margins can overcome prior expectations. Results for the .025 level 
and use of minimum expected P-values give similar results. 
In interpreting these results bear in mind that although 34 sites are potential contenders 
for selection, in a single experiment the number with at least one tumor is far smaller. 
Again, conditioning has dramatically changed the a priori situation. Table 4 displays the 
median and range for these numbers when ALL is a contender. This dramatic reduction in 
actual contenders supports Haseman 's and Mantel's view that one should not adjust for 
multiplicity by multiplying the minimum observed P-value by the number of potential 
contenders. Of course, the smaller number of contenders does help our conditional 
approach do well, but this reduction is inherent in the bioassay. 
Figure 2 plots the empirical cumulative distribution functions for the P-values selected by 
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the various rules using the Blom adjustment. As can be seen, the E_05 approach produces a 
distribution that is between that for unadjusted (PMIN) and the number of sites adjusted 
(KPMIN) minimum observed P-values. In fact, it corresponds very closely to the curve for 
square root of sites adjusted minimum P-values (not plotted). At the 5% P-value, the E_05 
and the KMIN curves superimpose, consistent with the findings in Table 3. These stochas-
tic relations suggest that for small P-values the conditional approach is picking up the 
same signals as those based on minimum observed P-values, while protecting the inference 
from multiplicity. 
We computed score tests and chi-square type statistics for each site-type combination 
based on selected sites and on all sites. If our model is correct, the score tests should 
approximately follow a standard normal distribution (though correlations among sites 
make this assumption less tenable when more than one site from each experiment is used). 
Summary statistics indicate that our conditional expected power model under-predicts the 
power (the score statistics are positive), but the scores generally fall below the 2.5% Gaus-
sian cut point. The chi-square statistics support the hypothesis of binomial variation. 
The expected P-value model produces negative scores (indicating that the observed P-
values tend to be smaller than expected), a finding consistent with under-predicting the 
power. 
5. THEORETICAL BACKGROUND 
5.1 General setting 
In this section we analyze a simplified model to investigate the potential power of selection 
strategies. We compare a selection strategy to the exact Bonferroni adjustment of the 
minimum P-value from independent tests. Of course, comparison with the unadjusted or 
Y K adjusted minimum P-value would produce results less favorable to a selection 
17 
strategy. Our simplified notation disguises the feature that the selection strategy can 
depend on coordinate-specific priors and conditioning information, but the analysis applies 
to these cases. The tests in our application are most likely dependent, so these results do 
not directly apply, but do provide support for the efficacy of the selection strategy. 
Consider two strategies for interpreting the results of K independent hypothesis tests: 
One (R ), selects a test according to a probability distribution w = ( w11 ... , wK), and the 
other (M) adjusts the smallest observed P-value by the exact Bonferroni method. The pro-
bability vector w can depend on prior distributions and conditioning statistics, but not on 
the observed P-values. We want to compare the statistical power of the two procedures 
under various alternatives and values of K. Let PVALw be the observed P-value for the 
random selection strategy and PVAL~ be the unadjusted observed P-value for the 
minimum P-value strategy. Then, the exact Bonferroni adjustment method converts 
PVAL~ to: 
Assume continuous distributions for all P-values and denote a cdf for a P-value by F8, 
with e .... O the null (F0 is uniform [0,1] ), and e > 0 the alternative. Then, if 
e- (811 ••• ,eK) is the true model, the distributions of PVALw and PVALK are: 
(5.1) 
and, with P == 1-a, 
pr(PVALK >uJ8J• I] (1- F,,(1-P })] . (5.2) 
Under H0 : 9 = 0, PVALw and PVALK have uniform distributions. Under alternatives we 
have the following: 
Theorem\: If 8 >O (component-wise), then both test procedures are unbiased. 
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proof: In this case, since every component of 8 is ·in the alternative space, Fe ( u) ~ u for 
t 
all ue[O,l] and all k. Therefore, both (5.1) and (5.2) evaluate to Sl-a, proving the 
result. 
If some coordinates of I are negative, then the tests may be biased. Bias can be prevented 
in procedure R by putting large weight on the components with positive e 'a. Procedure M 
can be protected only by eliminating coordinates with negative e 'a. These ideas underly 
Mantel's (1980) discussion of controlling the size of the overall test procedure. 
At a given significance level, a, power comparisons between Rand M depend on (5.1) and 
(5.2). If (5.1) is amaller than {5.e}, then procedure R is more powerful. 
5.2 Analysis as K -.co. 
Consider first the case where 81 = 92 == · · · = 9 K = 9. 
Theorem 5.2: For all K and all w: 
pr(PVALw>a IS)== 1- F 8(a), (5.3) 
and 
r r J(!100 pr(PVALK >a le)""' (1-a) •, (5.4) 
where f8 = f8(0); the density of the P-value distribution evaluated at 0. 
proof: Equation (5.3) is simply (5.1) under the condition of the theorem. Under this con-
dition, the right-hand side of(5.2) becomes: 
[ !- F, (1-~~1r 
.!.. 
To simplify taking limits write PK"" u, so K ... log(f3 )/log( u), and the log of the right-hand 
side becomes: 
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1 ( ) log[l-F9(1-u)] og J3 log( u) ' 
and we want the limit as u-1. l'Hopital's rule produces the result. 
Note that f0 can be 0 or oo and depends on the characteristics of the tail of the distribution 
of the underlying random variable producing the P-values. 
Theorem 5.2 can be generalized to the case where the 8 's come from a distribution G. 
Then, we obtain: 
pr(PVALwG>alG)= 1-f w0 (8)F9(a)dG(8), 
with J w0 (8) dG(8)'"" 1, and 
(5.3') 
(5.4') 
We conjecture that (5.3) is always greater than (5.4). If so, then for K large and all corn-
ponents having equal power, the adjusted minimum P-value strategy will have greater 
power than any selection strategy. Formulae (5.3') and (5.4') show, however, that when 
the 8' s vary sufficiently, intelligent selection rules ( w0 ) can be more powerful. Recall that 
procedure R can use conditioning information and coordinate-specific priors. Dependency 
of the weight function w0 (8) on 8 should be interpreted as allowing these dependencies. 
Specializing the above to the case where the test statistics producing the P-values come 
from a common location family with location parameters I, we find: 
Theorem 5.3: If the location family has distribution H with density h, then: 
r .... lim h(z-8) 
0 z ... oo h(z) · 
proof: A straightforward adaptation of the proof of Theorem 5.2. 
When the tail of h damps exponentially such as for the logistic and bilateral exponential 
distributions, f9 ""' exp(8). For e > 0 (5.3) is greater than (5.4) and procedure M is more 
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powerful than R. However, as mentioned previously, when the 6' a vary, intelligent selec-
tion rules can make R better than M. 
For the Gaussian distribution, f9 equals oo l or 0 according as 0 is greater than, equal to, or 
less than 0. This result implies that if G puts any mass on the positive real line, procedure 
M has asymptotic power equal to l. If G has finite, positive real line support, then M is 
asymptotically better than R. But, if G has unbounded positive support, then R can com-
pete by placing large weight on e[K]' the largest e in the sample. Analysis of this race to 
asymptosis requires comparison of the tails of H and G. 
5.3 The case K ... 2 
If the 01 - 92 > 0, then for the logistic and bilateral exponential examples, procedure M 
has higher power than R. If the 6 'a differ sufficiently, then placing large weight on the 
larger gives R higher power than M. In the Gaussian example relations depend on the size 
of the test, Ot. 
6. DISCUSSION 
The present analysis is primarily demonstrative. Our data-base does not contain informa-
tion on time to tumor, dose, or cause of death. Conditional selection procedures using this 
information depend on straightf'orward technical generalizations of the Carlin and Louis 
procedure. But, specifying priors for target and nuisance parameters and implementing 
the selection rule pose serious challenges. Even with the current data each step of the 
analysis could be improved. Estimated priors could incorporate the full effect of estimat-
ing parameters (Morris 1983, Laird and Louis 1986), or the non-parametric maximum likel-
ihood estimate of priors (Laird 1982) could replace those based on the Gaussian assump-
tion. In practice, priors should be developed using a combination of information on chemi-
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cals with similar structure and expert opinion. Models could combine evidence on the pri-
ors over gender and strain. 
Results indicate that the use of empirical priors to compute summaries of the conditional 
distribution of P-values has an empirical rejection rate competitive with the common 
approach of selecting the smallest observed P-value, and controls the statistical size of the 
overall procedure. Though we have no gold standard to assess the statistical power, 
theoretical calculations show that such selection procedures have potentially high power. 
The results should be interpreted as an upper bound on the performance of the conditional 
selection procedures, for we use the same data to estimate the priors and evaluate the pro-
cedure. There is some distance between the data used for prior estimation and assessment 
of performance, since we use all doses to estimate priors, but apply the method to high 
dose versus control comparisons. We could employ the bootstrap or jackknife (Efron 1982) 
for a more valid assessment, and expect our qualitative conclusions would hold up. 
Though the regulatory setting is too complicated to permit selection of a single site for 
analysis, use of our procedure to prioritize sites will focus debate. If statistical significance 
appears in a low-priority site, the burden of proof will be to justify the finding. If a high-
priority site is significant, the burden switches to arguing why the result should not be 
believed. As important, much of the debate would occur before the experiment during the 
construction of priors. As section 5 shows, even if the priors are misspecified, the size of 
the procedure is controlled, though the power will be reduced. This protection results from 
using the Bayesian structure to selec:t site, but a frequentist analysis that conditions on 
table marginals. This conditioning reduces information, and this loss can be considerable 
for high or low prevalence tum ors. A full Bayesian analysis could be performed, but would 
require even greater consensus on priors ·and generate its own controversy in place of the 
multiplicit,y problem. 
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Finally, we should remember that statistical significance computed from P-values provides 
only one type of input into the risk assessment process. Yet, P-values do carry a great 
deal of weight, and increasing their validity will improve the risk assessment process. The 
previously noted extensions and refinements will be required before the selection pro-
cedure becomes "on-line". This development depends on the efforts and expertise of Toxi-
cologists, Pathologists, Statisticians, Computer scientists and other experts. However, the 
effort and expense should be justified by the expense of the bioassay and its importance in 
the risk assessment process. 
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TABLE lA 
ESTIMATED PRIORS FOR MALE MICE for sites with information 
on e in at least 10 expts. 
SITE K 100 m c E(0) s.d.(0) 
ALL 23 29 10 .88 1.76 
SURV 23 68 3 -.34 1.84 
LI 932 11 1 1112 .58 2.54 
LI 934 24 19 13 .79 1.95 
LI 939 
LN 939 11 3 81 -.04 .26 
"" LU 904 13 3 21 .33 .18 
MG 902 
MU 939 23 5 15 -.44 .09 
PI 902 
SK 924 12 1 15 .06 .69 
SK 972 







ESTIMATED PRIORS FOR FEMALE MICE for sites with 
information on e in at least 10 expts. 
SITE K 100 m c E(0) s.d.(0) 
ALL 22 24 15 .76 1.88 
SURV 23 80 6 -.58 .49 
LI 932 
LI 934 22 4 84 1.61 2.41 
LI 939 13 1 84 .06 .95 
LN 939 13 2 65 .43 3.53 
LU 904 12 2 59 -.11 .24 
MG 902 











ESTIMATED PR I ORS FOR MALE RATS for sites with information 
on e in at least 10 expts. 
SITE K 100 m c E(0) s.d.(0) 
ALL 24 27 17 .00 2.35 
SURV 24 62 5 -.26 .82 
LI 932 
LI 934 11 1 233 . 1.26 1.84 
LI 939 
LN 939 
LU 904 10 2 233 -.23 3.18 
MG 902 
MU 939 24 13 16 -.50 1.02 
PI 902 
SK 924 11 2 63 -.42 1. 58 
SK 972 10 1 75 1. 00 3.39 
SP 932 
SP 939 
TH 908 12 2 1007 -.09 .28 




ESTIMATED PRIORS FOR FEMALE RATS for sites with 
information on e in at least 10 expts. 
SITE K 100 m c E(9) s.d.(0) 
LL 24 21 24 .41 1.22 






MG 902 18 2 906 .89 .54 
MU 939 19 10 77 -.58 1.88 
PI 902 13 4 57 -1.05 .23 
SK 924 
SK 972 10 1 103 -.45 4.26 
SP 932 
SP 939 
TH 908 12 4 880 -.33 .52 
TH 926 
UT 902 16 1 49 -.38 .34 
28 
Table 2: Tumor types associated with the Table 1 codes 
SURV ..,. survival until terminal sacrifice 
ALL = any malignancy 
Ll932 = liver hemangiosarcoma 
LI934 = liver hepatocellular carcinoma 
Ll939 ... liver lymphosarcoma 
LN939 = lymph node lymphosarcoma 
LU904 "" lung alveolar /bronchiolar carcinoma 
MG902 "" mammary gland adenocarcinoma 
MU939 = multiple organs lymphosarcoma 
PI902 = pituitary adenocarcinoma 
SK924 - skin fibrosarcoma 
SK972 = skin squamous cell carcinoma 
SP932 = spleen hemangiosarcoma 
SP939 = spleen lymphosarcoma 
TH908 "" thyroid c-cell carcinoma 
TH926 = thyroid follicular cell carcinoma 
UT902 = uterus adenocarcinoma 
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Table 3: Joint frequencies of statistically significant results for 
the EP.05 selection criterion. The first row of each 
table indicates significance at the .05 level for minimum 
(adjusted) observed P-values and the first column 
indicates significance for the EP.05 criterion. Since 
table totals for all but the combined tables equal 24 or 
25, probabilities (times 100) can be obtained by 






































































Table 4: Median and range of the nuaber of sites with a least one tuaor 
<including ALL>, and aost frequently selected sites. A blank 






































MU939 6 9 not investigated 
LU904 5 2 
Figure 1: A typical 2x2 table coaparing a dose group and control 
Control Treated I Total 
----------1--------------------------1-------------
Tuaor I a-t t I • 
I 
lo Tuaor I no-a-t n1-t I n+ - s 
-------------1--------------------------1-------------
1 I 














































FIGURE 2: Estimated cumulative distributions of P-values 
for the minimum observed (PMIN), conditional 
expected power (E.05), and Bonferroni adjusted 
(KPMIN) decision rules. 

